Payment overview · 2025
General Payments
$1,484.37
59 reported records · 20 companies
Healthcare provider profile · identity verified
Elisabeth Anne Sciotto, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · COLORADO SPRINGS, CO · NPI 1699027565
Verified facts
What the public records show
CMS Open Payments records show Elisabeth Anne Sciotto, NP-C received $1,484.37 in general payments during 2025 across 59 reported records.
ABBVIE INC. accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $314.06 | 21.2% | 14 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $251.15 | 16.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $232.33 | 15.7% | 19 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $107.05 | 7.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.99 | 5.8% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $71.60 | 4.8% | 2 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $64.81 | 4.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $35.83 | 2.4% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.76 | 2.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $34.31 | 2.3% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $33.98 | 2.3% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.41 | 2.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $27.08 | 1.8% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $26.61 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.15 | 1.7% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $24.75 | 1.7% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $23.15 | 1.6% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.27 | 1.5% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.03 | 1.5% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.05 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,437.38 | 58 |
| Education | $46.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $314.06 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $281.39 | 13 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $251.15 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $171.49 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $171.49 | 9 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $107.05 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $71.60 | 2 | 2025 |
Source payment records
|
|||||
| VNS Therapy Normalized: vns therapy |
Device | LivaNova USA, Inc. | $64.81 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $60.84 | 10 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $55.81 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $35.76 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $34.31 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $33.98 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $29.41 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $27.08 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $26.61 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 189 | 56 |
| Lisinopril | Lisinopril | 157 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 143 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 40 |
| Metformin Hcl | Metformin Hcl | 92 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 85 | 30 |
| Omeprazole | Omeprazole | 80 | 26 |
| Gabapentin | Gabapentin | 75 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 53 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 19 |
| Losartan Potassium | Losartan Potassium | 44 | 16 |
| Potassium Chloride | Potassium Chloride | 44 | 11 |
| Alprazolam | Alprazolam | 40 | suppressed |
| Furosemide | Furosemide | 40 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 38 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Simvastatin | Simvastatin | 32 | 11 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,484.37 · 59 records | ABBVIE INC. | ACTHAR, AREXVY, BRIUMVI, GOMEKLI, INGREZZA, Leqembi, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, Rystiggo, SHINGRIX, Symbravo, UBRELVY, ULTOMIRIS, UPLIZNA, VNS Therapy, VYEPTI, XYWAV, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error